Take2 Health Settled in Qianhai Kerry Centre, Shenzhen, Laying the Foundation for Business Expansion
In pursuit of following the prudent strategies for long-term business development, Take2 Health (hereinafter referred to as "we" or "our company") has officially settled in Qianhai Kerry Centre, Shenzhen, in 2021 year-end. The settlement marked a significant milestone as we established the first operating base outside the Hong Kong Special Administrative Region. Furthermore, by making early nasopharyngeal cancer (“NPC”) detection services widely available in the Guangdong-Hong Kong-Macao Greater Bay Area (“GBA”), we are dedicated to continuously improving the overall health of the general public.
Shenzhen office in the prime location equipped with a high standard laboratory capable of serving a large population
Located in the prime area of Qianhai, our office and laboratory is adjacent to the Guangzhou-Shenzhen Yanjiang Expressway, giving our company geographically distinctive and favourable advantages which at the same time attract plenty of high-tech companies and talents. Our state-of-the-art medical laboratory (over 2,000 sq.m.) upholds laboratory quality control standards according to The National Basic Standards and Management Specifications for Medical Laboratory, ISO15189 and CAP. From a long-term perspective, we expect to provide services to the vast population in the GBA and across China with a large-scale operation.
The new site is designed to enhance in-house productivity and service quality with the office and laboratory built-in side-by-side. To enable our utilisation of the Next-generation Sequencing technology, we uphold corresponding stringent guidelines throughout the construction and establishment. Also, the laboratory is equipped with a stable electricity supply and refrigerating system to ensure temperature and humidity control alongside cleanliness. To reduce the risk of cross-contamination, separate routes have been designed for visiting and laboratory staff respectively with the ventilation facility and buffer zone built in place.
Deep-rooted in Hong Kong, we are determined to co-build the league to fight against nasopharyngeal cancer in Guangdong-Hong Kong-Macao Greater Bay Area
Tony Yung, CEO of Take2 Health, said: “In the light of the Central Government’s promulgation of 14th Five-Year Plan for National Economic and Social Development and Long-Range Objectives for 2035, it is vital to promote the cooperation along the Guangzhou-Shenzhen Science and Technology Innovation Corridor. With the guidance and assistance provided by the Qianhai Administration, we are grateful to be successfully settled in the GBA now. While Hong Kong is where we started, the GBA will be another base for providing our service. Our company is dedicated to becoming the pioneering force in the early cancer detection industry by providing our accurate and reliable early cancer detection service. In addition, we are determined to facilitate shaping the GBA area to be the NPC “early detection and early treatment” model region. Furthermore, our company is committed to co-build the league to fight against NPC with top universities and hospitals to improve the well-being of the public.
To become the frontier runner in the industry, our company is focusing on providing early NPC detection services in the GBA. Looking ahead, we will continue to increase the accessibility of our medical innovation in the GBA, in entire mainland China and across Asia.
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)